Welcome to PharmaCyte BioTech
An OTCQB Company
PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.
FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment
European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary,
PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment
PharmaCyte Biotech, Inc.
$122,386,272 a/o Dec 19, 2016
848,904,665 a/o Aug 29, 2016
1,490,000,000 a/o Aug 26, 2014
817,204,665 a/o Aug 29, 2016
For more updated information please visit:
Signature Stock Transfer Inc. Plano TX Ph # 972-612-4120
Stonegate Capital Inc.
8201 Preston Road
Dallas, TX 75225
All News Releases:
What is Cell-in-a-Box®?
The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.
Kenneth L. Waggoner, Chief Executive Officer and President
Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director
Carlos A. Trujillo – Chief Financial Officer and Director
Walter H. Gunzburg – Chief Scientific Officer
Dr. Matthias Lohr as Chairman of Scientific Advisory Board
Thomas Liquard - Chairman of the Audit Committe
Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development
Dr. Manuel Hidalgo, Scientific Advisory Board
- The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
- We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
- There are no guarantees when buying or selling any security.